TY - JOUR
T1 - Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma
AU - Cannon, C.
AU - Borgatti, A.
AU - Henson, M.
AU - Husbands, B.
N1 - Publisher Copyright:
© 2015 British Small Animal Veterinary Association.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - OBJECTIVES: To describe a chemotherapy protocol combining lomustine and doxorubicin in canine histiocytic sarcoma, including outcomes and toxicity. MATERIALS AND METHODS: Retrospective review of case records for dogs with histiocytic sarcoma treated with lomustine and doxorubicin (± cyclophosphamide) alternating every 2 weeks. Data collected included signalment, clinical signs, clinicopathological abnormalities, extent of disease, response, toxicity, time to tumour progression and survival time. RESULTS: Of 17 dogs, 15 had disseminated or metastatic disease. The median number of chemotherapy cycles (one dose of each drug) received was three; most dogs discontinued therapy due to progressive disease. Dose reductions or delays occurred in 18% of cycles. The overall response rate was 58%, with a median time to tumour progression of 185 (range, 59 to 268) days for responders. The overall median survival time was 185 (18 to 402) days. No significant prognostic factors were identified. CLINICAL SIGNIFICANCE: The protocol appeared well-tolerated, had some efficacy against canine histiocytic sarcoma in the study population and could be considered as an alternative to single-agent protocols; prospective comparison may be warranted.
AB - OBJECTIVES: To describe a chemotherapy protocol combining lomustine and doxorubicin in canine histiocytic sarcoma, including outcomes and toxicity. MATERIALS AND METHODS: Retrospective review of case records for dogs with histiocytic sarcoma treated with lomustine and doxorubicin (± cyclophosphamide) alternating every 2 weeks. Data collected included signalment, clinical signs, clinicopathological abnormalities, extent of disease, response, toxicity, time to tumour progression and survival time. RESULTS: Of 17 dogs, 15 had disseminated or metastatic disease. The median number of chemotherapy cycles (one dose of each drug) received was three; most dogs discontinued therapy due to progressive disease. Dose reductions or delays occurred in 18% of cycles. The overall response rate was 58%, with a median time to tumour progression of 185 (range, 59 to 268) days for responders. The overall median survival time was 185 (18 to 402) days. No significant prognostic factors were identified. CLINICAL SIGNIFICANCE: The protocol appeared well-tolerated, had some efficacy against canine histiocytic sarcoma in the study population and could be considered as an alternative to single-agent protocols; prospective comparison may be warranted.
UR - http://www.scopus.com/inward/record.url?scp=84933676887&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84933676887&partnerID=8YFLogxK
U2 - 10.1111/jsap.12354
DO - 10.1111/jsap.12354
M3 - Article
C2 - 25828786
AN - SCOPUS:84933676887
SN - 0022-4510
VL - 56
SP - 425
EP - 429
JO - Journal of Small Animal Practice
JF - Journal of Small Animal Practice
IS - 7
ER -